...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Quantification of hTERT mRNA and Telomerase Activity in Bladder Washings of Patients with Recurrent Urothelial Cell Carcinomas
【24h】

Quantification of hTERT mRNA and Telomerase Activity in Bladder Washings of Patients with Recurrent Urothelial Cell Carcinomas

机译:复发性尿路上皮细胞癌患者膀胱冲洗液中hTERT mRNA和端粒酶活性的定量

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In patients with superficial urothelial cell carcinomas (UCCs), 80% of tumors recur after transurethral resection. A minority (10–20%) of these recurrent tumors will progress to high-grade and muscle-invasive disease (1). Prediction of progression would enable the urologist to determine individual therapy to reduce mortality.For the detection of recurrent disease, endoscopic evaluation (cystoscopy) is considered the gold standard (1). Cystoscopy is supplemented with urine or bladder wash cytology that can detect cells from carcinoma in situ (CIS) or small high-grade tumors, both of which greatly increase progression risk and frequently are missed with cystoscopy (1)(2). Unfortunately, cytology is susceptible to observer variability, and a more standardized method for exfoliated tumor cell analysis is needed (3).Telomerase is a promising tumor marker that can be detected in 95% of all UCCs, but not in healthy urothelia (4). However, the relationship between telomerase activity and prognostic indicators, such as stage and grade, is not clear (4)(5)(6). As a more quantitative alternative, we developed a method to assess the expression of the hTERT gene, which codes for the catalytic subunit of telomerase (7). An endogenous control ( 18S rRNA expression) was included in this assay to normalize for conditions affecting the accurate quantification of hTERT mRNA. Application of the novel method to bladder tissue samples showed that all UCCs, but no healthy urothelia, expressed hTERT (8). Moreover, a significant correlation was found with clinicopathological indices (8). When we applied cutoff values for normalized hTERT , the assay could discriminate between low, medium, and high-grade UCCs (8). This suggested that the presence of hTERT mRNA is not only a diagnostic marker, but when quantified accurately, may also be used as a prognostic marker. In this study, we investigated whether aggressive exfoliated tumor cells can be identified by quantification …
机译:在浅表性尿路上皮细胞癌(UCCs)患者中,经尿道切除后会复发80%的肿瘤。这些复发性肿瘤中的少数(10–20%)将发展为高级别的肌肉侵袭性疾病(1)。进展的预测将使泌尿科医生能够确定降低死亡率的个体疗法。对于复发性疾病的检测,内镜评估(膀胱镜)被认为是金标准(1)。膀胱镜检查补充了尿液或膀胱冲洗细胞学检查功能,可以检测到原位癌(CIS)或小规模高级别肿瘤中的细胞,这两种方法都大大增加了进展风险,膀胱镜检查常常会漏掉它们(1)(2)。不幸的是,细胞学容易受到观察者变异的影响,因此需要更标准化的脱落肿瘤细胞分析方法(3)。端粒酶是一种有前途的肿瘤标志物,可以在95%的所有UCC中检出,但在健康的尿路上皮中则无法检出(4)。 。但是,端粒酶活性与预后指标(如阶段和等级)之间的关系尚不清楚(4)(5)(6)。作为更定量的选择,我们开发了一种方法来评估hTERT基因的表达,该基因编码端粒酶的催化亚基(7)。在该测定法中包括内源性对照(18S rRNA表达)以对影响hTERT mRNA准确定量的条件进行标准化。将该新方法应用于膀胱组织样品显示,所有UCC均表达hTERT,但无健康的尿路上皮(8)。此外,还发现与临床病理指标之间存在显着相关性(8)。当我们为归一化的hTERT应用临界值时,该分析可以区分低,中和高等级的UCC(8)。这表明,hTERT mRNA的存在不仅是诊断标记,而且当准确定量时,也可以用作预后标记。在这项研究中,我们调查了是否可以通过定量鉴定侵袭性脱落的肿瘤细胞……

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号